CHMP issues positive opinion on CYT387
Earlier, the company has received orphan drug status for CYT387 for the treatment of myelofibrosis from the US Food and Drug Administration (FDA). YM BioSciences president and CEO
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The agreement covers kinetoplastid diseases (leishmaniases, Chagas disease, and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis), and dracunculiasis, fascioliasis, and schistosomiasis diseases. Under the